Get the Stockscreener App
3.87
5.38%
-0.22
After Hours:
3.90
0.03
+0.78%
Unicycive Therapeutics Inc stock is traded at $3.87, with a volume of 1.17M.
It is down -5.38% in the last 24 hours and down -8.94% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$4.09
Open:
$4.2
24h Volume:
1.17M
Relative Volume:
0.59
Market Cap:
$68.35M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-2.4968
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-11.24%
1M Performance:
-8.94%
6M Performance:
+556.60%
1Y Performance:
+918.42%
1-Day Range:
$3.82
$4.21
1-Week Range:
$3.82
$4.43
52-Week Range:
$0.34
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
3.87 | 75.77M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY - GlobeNewswire Inc.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
October 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against UNCY - PR Newswire
Important Notice to Long-Term Shareholders of Applied - GlobeNewswire
UNCY Investors have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - MarketScreener
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to C - PharmiWeb.com
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors in Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your RightsUNCY - MarketScreener
Shareholders that lost money on Unicycive Therapeutics, - GlobeNewswire
Securities Lawsuit Alert: Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky Before October 14, 2025 - ACCESS Newswire
Real time alert setup for Unicycive Therapeutics Inc. performance - Newser
Unicycive Therapeutics, Inc. (UNCY) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 14, 2025 - ACCESS Newswire
Unicycive Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025UNCY - Morningstar
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Urged to Join Class Action Before October 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Using portfolio simulators with Unicycive Therapeutics Inc. included2025 Price Momentum & Target Return Focused Stock Picks - Newser
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain OfficersUNCY - WV News
UNCY LAWSUIT ALERT: The Gross Law Firm Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com
Tools to monitor Unicycive Therapeutics Inc. recovery probabilityJuly 2025 PostEarnings & Risk Managed Investment Entry Signals - Newser
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Is Unicycive Therapeutics Inc. stock good for income investors2025 Pullback Review & Target Return Focused Stock Picks - beatles.ru
Securities Fraud Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY)Levi & Korsinsky Reminds Investors of October 14, 2025 - ACCESS Newswire
Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before October 14, 2025 - ACCESS Newswire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi Reminds Unicycive Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 - GlobeNewswire Inc.
Will Unicycive Therapeutics Inc. stock recover after recent dropTrade Analysis Summary & Community Verified Swing Trade Signals - Newser
UNCY ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Unicycive Therapeutics, Inc.October 14, 2025 Deadline - ACCESS Newswire
Is Unicycive Therapeutics Inc. stock entering bullish territoryLong Setup & Risk Adjusted Swing Trade Ideas - Newser
Nantahala Capital Management LLC Reduces Holdings in Unicycive Therapeutics, Inc. $UNCY - MarketBeat
Unicycive Therapeutics' Securities Lawsuit: Strategic Investor Considerations Amid Regulatory and Legal Challenges - AInvest
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCY - FinancialContent
Unicycive Therapeutics Investigated for Securities Violations by Faruqi & Faruqi. - AInvest
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics - MarketScreener
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Unicycive Therapeutics, Inc. (UNCY) | FinancialContent - FinancialContent
Is Unicycive Therapeutics Inc. impacted by rising ratesAnalyst Upgrade & Safe Entry Trade Reports - خودرو بانک
UNCY Investors: If you Lost Significant Money in UNCY Contact Robbins LLP for Information About the Securities Fraud Class Action Against Unicycive Therapeutics, Inc. - Morningstar
The Risks of Over-Optimism in Telecommunications: A Case Study of Unicycive Therapeutics and Charter Communications Class-Action Allegations - AInvest
UNCY Investors: Robbins LLP Investigates Securities Fraud Class Action Against Unicycive Therapeutics, Inc. - AInvest
Unicycive Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
How does Unicycive Therapeutics Inc. score in quality rankingsPrice Action & Fast Momentum Stock Entry Tips - خودرو بانک
Unicycive Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky ... - Bluefield Daily Telegraph
Shareholders SueWallSt in New Class Action Against Unicycive Therapeutics, Inc.Act Now - Nasdaq
Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (UNCY) to a Class Action Deadline on October 14, 2025 - FinancialContent
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Silicon Valley - FinancialContent
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 14, 2025 in Unicycive Therapeutics, Inc. LawsuitUNCY - PR Newswire
What indicators show strength in Unicycive Therapeutics Inc.2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Risk adjusted return profile for Unicycive Therapeutics Inc. analyzed2025 Analyst Calls & AI Enhanced Execution Alerts - Newser
Custom watchlist performance reports with Unicycive Therapeutics Inc.Swing Trade & Free Risk Controlled Daily Trade Plans - Newser
Securities Class Action Lawsuit Filed Against Unicycive Therapeutics, Inc. (UNCY)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Class Action Lawsuit Filed: Unicycive Therapeutics, Inc. (UNCY)Join by October 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):